Critical Limb Ischemia


Aastrom To Refocus Research On Dilated Cardiomyopathy, Cut Staff

Aastrom Biosciences Inc., a developer of patient-specific expanded multicellular therapies for the treatment of severe chronic diseases, announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy.

WWJ Newsradio 950–03/27/2013


Aastrom Board Names Dominick C. Colangelo President, CEO

Aastrom Biosciences Inc. announced that the company’s board of directors has named Dominick C. Colangelo as president and CEO.

WWJ Newsradio 950–03/07/2013